153 related articles for article (PubMed ID: 38297352)
41. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P
JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841
[TBL] [Abstract][Full Text] [Related]
42. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).
Sikov WM; Berry DA; Perou CM; Singh B; Cirrincione CT; Tolaney SM; Kuzma CS; Pluard TJ; Somlo G; Port ER; Golshan M; Bellon JR; Collyar D; Hahn OM; Carey LA; Hudis CA; Winer EP
J Clin Oncol; 2015 Jan; 33(1):13-21. PubMed ID: 25092775
[TBL] [Abstract][Full Text] [Related]
43. Survival analysis of the randomised phase III GeparOcto trial comparing neoadjuvant chemotherapy of intense dose-dense epirubicin, paclitaxel, cyclophosphamide versus weekly paclitaxel, liposomal doxorubicin (plus carboplatin in triple-negative breast cancer) for patients with high-risk early breast cancer.
Schneeweiss A; Michel LL; Möbus V; Tesch H; Klare P; Hahnen E; Denkert C; Kast K; Pohl-Rescigno E; Hanusch C; Link T; Untch M; Jackisch C; Blohmer JU; Fasching PA; Solbach C; Schmutzler RK; Huober J; Rhiem K; Nekljudova V; Lübbe K; Loibl S;
Eur J Cancer; 2022 Jan; 160():100-111. PubMed ID: 34801353
[TBL] [Abstract][Full Text] [Related]
44. Metabolic Characterization of Inflammatory Breast Cancer With Baseline FDG-PET/CT: Relationship With Pathologic Response After Neoadjuvant Chemotherapy, Receptor Status, and Tumor Grade.
Jacene HA; Youn T; DiPiro PJ; Hu J; Cheng SC; Franchetti Y; Shah H; Bellon JR; Warren L; Schlosnagle E; Nakhlis F; Rosenbluth J; Yeh E; Overmoyer B;
Clin Breast Cancer; 2019 Apr; 19(2):146-155. PubMed ID: 30584057
[TBL] [Abstract][Full Text] [Related]
45. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
[TBL] [Abstract][Full Text] [Related]
46. Phase I-II study of the farnesyl transferase inhibitor tipifarnib plus sequential weekly paclitaxel and doxorubicin-cyclophosphamide in HER2/neu-negative inflammatory carcinoma and non-inflammatory estrogen receptor-positive breast carcinoma.
Andreopoulou E; Vigoda IS; Valero V; Hershman DL; Raptis G; Vahdat LT; Han HS; Wright JJ; Pellegrino CM; Cristofanilli M; Alvarez RH; Fehn K; Fineberg S; Sparano JA
Breast Cancer Res Treat; 2013 Oct; 141(3):429-35. PubMed ID: 24068539
[TBL] [Abstract][Full Text] [Related]
47. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
48. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2.
Mohamed HT; El-Ghonaimy EA; El-Shinawi M; Hosney M; Götte M; Woodward WA; El-Mamlouk T; Mohamed MM
Toxicol Appl Pharmacol; 2020 Aug; 401():115092. PubMed ID: 32512068
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of weekly paclitaxel plus carboplatin followed by anthracycline chemotherapy on the neoadjuvant treatment of patients with triple-negative breast cancer.
Castrellon AB; Velez M; Nguyen SM; Blaya M; Barnick S; Dumais K; LeCroy N; Raez LE
Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):30-33. PubMed ID: 29100977
[TBL] [Abstract][Full Text] [Related]
50. Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer†.
Gonzalez-Angulo AM; Akcakanat A; Liu S; Green MC; Murray JL; Chen H; Palla SL; Koenig KB; Brewster AM; Valero V; Ibrahim NK; Moulder-Thompson S; Litton JK; Tarco E; Moore J; Flores P; Crawford D; Dryden MJ; Symmans WF; Sahin A; Giordano SH; Pusztai L; Do KA; Mills GB; Hortobagyi GN; Meric-Bernstam F
Ann Oncol; 2014 Jun; 25(6):1122-7. PubMed ID: 24669015
[TBL] [Abstract][Full Text] [Related]
51. Phase II trial of combination of pegylated liposomal doxorubicin, cisplatin, and infusional 5-fluorouracil (CCF) plus trastuzumab as preoperative treatment for locally advanced and inflammatory breast cancer.
Torrisi R; Cardillo A; Cancello G; Dellapasqua S; Balduzzi A; Ghisini R; Luini A; Veronesi P; Viale G; Goldhirsch A; Colleoni M
Clin Breast Cancer; 2010 Dec; 10(6):483-8. PubMed ID: 21147693
[TBL] [Abstract][Full Text] [Related]
52. [Systemic treatments of inflammatory breast cancer: an overview].
Monneur A; Bertucci F; Viens P; Gonçalves A
Bull Cancer; 2014 Dec; 101(12):1080-8. PubMed ID: 25475708
[TBL] [Abstract][Full Text] [Related]
53. Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study.
Tan AR; Johannes H; Rastogi P; Jacobs SA; Robidoux A; Flynn PJ; Thirlwell MP; Fehrenbacher L; Stella PJ; Goel R; Julian TB; Provencher L; Bury MJ; Bhatt K; Geyer CE; Swain SM; Mamounas EP; Wolmark N
Breast Cancer Res Treat; 2015 Jan; 149(1):163-9. PubMed ID: 25542269
[TBL] [Abstract][Full Text] [Related]
54. Light and shade of ruxolitinib: positive role of early treatment with ruxolitinib and ruxolitinib withdrawal syndrome in patients with myelofibrosis.
Baek DW; Cho HJ; Lee JM; Kim J; Moon JH; Sohn SK
Expert Rev Hematol; 2022 Jul; 15(7):573-581. PubMed ID: 35679520
[TBL] [Abstract][Full Text] [Related]
55. Neoadjuvant carboplatin in triple-negative breast cancer: results from NACATRINE, a randomized phase II clinical trial.
de Pádua Souza C; Carneiro ASB; de Oliveira Lessa AC; Lacerda DC; Paiva CE; Zorzetto MMC; de Freitas AJA; Santana IVV; de Oliveira MA; Palmero EI; Marques MMC; Reinert T
Breast Cancer Res Treat; 2023 Nov; 202(1):57-65. PubMed ID: 37578666
[TBL] [Abstract][Full Text] [Related]
56. Predictive Markers of Response to Neoadjuvant Durvalumab with Nab-Paclitaxel and Dose-Dense Doxorubicin/Cyclophosphamide in Basal-Like Triple-Negative Breast Cancer.
Blenman KRM; Marczyk M; Karn T; Qing T; Li X; Gunasekharan V; Yaghoobi V; Bai Y; Ibrahim EY; Park T; Silber A; Wolf DM; Reisenbichler E; Denkert C; Sinn BV; Rozenblit M; Foldi J; Rimm DL; Loibl S; Pusztai L
Clin Cancer Res; 2022 Jun; 28(12):2587-2597. PubMed ID: 35377948
[TBL] [Abstract][Full Text] [Related]
57. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
Guarneri V; Dieci MV; Bisagni G; Boni C; Cagossi K; Puglisi F; Pecchi A; Piacentini F; Conte P
Ann Surg Oncol; 2015 Sep; 22(9):2881-7. PubMed ID: 25572687
[TBL] [Abstract][Full Text] [Related]
58. Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report.
Kharel Z; Nemer OP; Xi W; Upadhayaya B; Falkson CI; O'Regan RM; Dhakal A
Breast Dis; 2022; 41(1):255-260. PubMed ID: 35599460
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies.
Papp K; Szepietowski JC; Kircik L; Toth D; Eichenfield LF; Leung DYM; Forman SB; Venturanza ME; Sun K; Kuligowski ME; Simpson EL
J Am Acad Dermatol; 2021 Oct; 85(4):863-872. PubMed ID: 33957195
[TBL] [Abstract][Full Text] [Related]
60. Subgroup analysis of Japanese patients in a phase III randomized, controlled study of neoadjuvant atezolizumab or placebo, combined with nab-paclitaxel and anthracycline-based chemotherapy in early triple-negative breast cancer (IMpassion031).
Saji S; Ohsumi S; Ito M; Hayashi N; Kobayashi K; Masuda N; Niikura N; Yamashita T; Kiyama K; Hasegawa A; Nakagawa S; Hattori M
Jpn J Clin Oncol; 2022 Oct; 52(10):1124-1133. PubMed ID: 35750038
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
